Enesi Pharma’s ImplaVax® platform shortlisted for Best New Vaccine Technology/Platform at the Vaccine Industry Excellence (ViE) Awards 2020

OXFORD, UK – 02 Mar 2020 – Enesi Pharma announces that its proprietary ImplaVax® solid dose, needle-free device and formulation technology has been shortlisted as a finalist for the Best New Vaccine Technology/Platform Award, the winner of which will be revealed at the 13th Annual Vaccine Industry Excellence (ViE) Awards ceremony and gala dinner on 7 April 2020. The Awards honour and recognize the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry and are a highlight of the World Vaccine Congress, taking place on 6 – 9 April in Washington, DC.

The World Vaccine Congress is a leading forum for discussing how cutting-edge research efforts can be integrated with pharma, biotech, academia and government to produce more and better vaccines to the market. In addition, the congress is expanding into newer topic areas such as BioDefense, Big Data and Bioinformatics in a greater capacity, engaging more profiles from Army, Department of Defense, non-profits and national representatives in healthcare.

David Hipkiss, Enesi CEO said

“We are delighted to have been short listed in the Best New Vaccine Technology/Platform category at such a prestigious global event. This recognises the outstanding efforts and progress of the Enesi Team in applying and leveraging our unique needle-free, unit solid dose, ImplaVax® vaccination technology to multiple targets, indications, populations and geographies over the last 12 months as we strive in our goal to make a material impact on global health.”